Quick Answer
CNS Pharmaceuticals, Inc. reported Operating Income of -$15.99 million for fiscal year 2025.
CNS Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$15.99M | -7.3% |
| 2024 | -$14.90M | +21.0% |
| 2023 | -$18.87M | -23.6% |
| 2022 | -$15.27M | -5.4% |
| 2021 | -$14.49M | -53.2% |
| 2020 | -$9.45M | -146.7% |
| 2019 | -$3.83M | -334.7% |
| 2018 | -$881.8K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.25M | +42.2% | -35.0% |
| June 30, 2025 | -$2.41M | +4.7% | +44.5% |
| March 31, 2025 | -$4.34M | -22.4% | +22.9% |
| September 30, 2024 | -$5.63M | -24.2% | -122.7% |
| June 30, 2024 | -$2.53M | +37.2% | +28.7% |
| March 31, 2024 | -$3.54M | +28.0% | +21.8% |
| September 30, 2023 | -$4.53M | -32.6% | -12.6% |
| June 30, 2023 | -$4.03M | -12.9% | +18.3% |
- CNS Pharmaceuticals, Inc. showed a decrease of -7.3% in Operating Income compared to the prior fiscal year.
- Over the 2018–2025 period, CNS Pharmaceuticals, Inc.’s operating income has declined by 1713.0% (from -$881.8 thousand to -$15.99 million).
- The most recent figure is from CNS Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: